Biofrontera Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 12, 2024, specifically the Company's Annual Meeting of Stockholders. Biofrontera Inc. is an emerging growth company incorporated in Delaware, with principal executive offices in Woburn, Massachusetts.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the Company's most recent 10-K or 10-Q filings for financial statements.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved an amendment to the 2021 Omnibus Incentive Plan, increasing the number of shares authorized for issuance by 3,483,010 shares. The total authorized shares increased from 266,990 to 3,750,000 shares.
- Director Elections: Stockholders elected John J. Borer III, JD, and Prof. Hermann Luebbert, Ph.D., to serve as Class III directors until the 2027 Annual Meeting.
- Auditor Ratification: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voting Results
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of John J. Borer III | 2,082,224 | 70,224 (Withheld) | N/A | 606,778 |
| Election of Prof. Hermann Luebbert | 2,092,691 | 59,804 (Withheld) | N/A | 606,731 |
| Amendment to Incentive Plan | 2,105,881 | 43,161 | 3,556 | 606,698 |
| Ratification of Auditor (Marcum LLP) | 2,749,654 | 5,670 | 3,902 | 0 |
Quorum: Holders of 2,759,226 votes were present, constituting a quorum.
Guidance, Outlook, and Risks
This filing does not contain management guidance, financial outlook, or specific risk factor updates beyond the standard disclosures referenced in the Proxy Statement. The primary focus is the successful execution of the Annual Meeting agenda.
Key Facts for Investor Verification
- Verify the dilution impact of the new 3,483,010 shares added to the 2021 Omnibus Incentive Plan.
- Confirm the tenure of the newly elected Class III directors (John J. Borer III and Prof. Hermann Luebbert) through 2027.
- Review the definitive Proxy Statement filed on April 30, 2024, for detailed terms of the amended Incentive Plan.
- Note that this 8-K contains no financial performance data; refer to recent 10-Q/10-K filings for fiscal health.